Bruker Corporation (NASDAQ:BRKR – Get Free Report)’s stock price crossed above its 50 day moving average during trading on Tuesday. The stock has a 50 day moving average of $58.79 and traded as high as $61.00. Bruker shares last traded at $60.74, with a volume of 2,384,762 shares.
Wall Street Analysts Forecast Growth
A number of research analysts recently commented on BRKR shares. UBS Group initiated coverage on Bruker in a research note on Wednesday, September 9th. They issued a “neutral” rating and a $65.00 price target for the company. JPMorgan Chase & Co. reaffirmed a “neutral” rating and issued a $60.00 target price on shares of Bruker in a report on Wednesday, October 14th. Guggenheim raised their target price on Bruker from $70.00 to $72.00 and gave the company a “buy” rating in a report on Thursday, October 1st. TD Cowen lifted their price target on Bruker from $60.00 to $62.00 and gave the company a “hold” rating in a research note on Tuesday, October 13th. Finally, The Goldman Sachs Group upgraded Bruker from a “strong sell” rating to a “strong-buy” rating in a research report on Monday, September 21st. Two analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $59.43.
View Our Latest Stock Report on Bruker
Bruker Trading Up 4.3%
The stock’s fifty day simple moving average is $58.79 and its two-hundred day simple moving average is $50.25.
Bruker (NASDAQ:BRKR – Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The medical research company reported $0.49 EPS for the quarter, topping analysts’ consensus estimates of $0.38 by $0.11. The business had revenue of $838.50 million for the quarter, compared to analyst estimates of $853.57 million. Bruker’s revenue for the quarter was up 5.2% on a year-over-year basis. During the same quarter last year, the firm posted $0.32 EPS. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, equities analysts predict that Bruker Corporation will post 2.12 earnings per share for the current fiscal year.
Bruker Dividend Announcement
The business also recently declared a quarterly dividend, which was paid on Wednesday, October 7th. Stockholders of record on Monday, September 21st were paid a $0.05 dividend. The ex-dividend date of this dividend was Monday, September 21st. This represents a $0.20 annualized dividend and a dividend yield of 0.3%.
Insider Activity at Bruker
In other Bruker news, VP Mark Munch sold 2,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 15th. The shares were sold at an average price of $52.87, for a total transaction of $105,740.00. Following the completion of the transaction, the vice president owned 134,806 shares in the company, valued at approximately $7,127,193.22. This trade represents a 1.46% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 27.20% of the stock is currently owned by corporate insiders.
Hedge Funds Weigh In On Bruker
Hedge funds have recently bought and sold shares of the company. Global Retirement Partners LLC acquired a new position in Bruker in the second quarter valued at $38,000. Root Financial Partners LLC acquired a new position in shares of Bruker in the 3rd quarter valued at about $57,000. Essential Partners LLC bought a new stake in shares of Bruker during the 1st quarter valued at about $36,000. FNY Investment Advisers LLC acquired a new stake in Bruker during the second quarter worth approximately $60,000. Finally, IFP Advisors Inc increased its holdings in Bruker by 88.6% in the second quarter. IFP Advisors Inc now owns 1,060 shares of the medical research company’s stock worth $64,000 after purchasing an additional 498 shares in the last quarter. Institutional investors own 79.52% of the company’s stock.
Bruker Company Profile
Bruker Corporation develops and manufactures scientific instruments, analytical systems and related software used to study materials, molecules and biological processes. Its technologies support research, discovery and quality control in fields including life sciences, pharmaceutical development, chemical analysis, materials science, environmental testing and clinical research.
The company’s product portfolio includes nuclear magnetic resonance and electron paramagnetic resonance systems, mass spectrometers, infrared and Raman spectroscopy instruments, X-ray analysis equipment, microscopy and nanoanalysis systems, and preclinical imaging technologies.
Read More
- Five stocks we like better than Bruker
- Coca-Cola Stock Is Everything AI Isn’t—And That’s Its Biggest Strength
- Apple’s Foldable iPhone Sold Out in Minutes, But Wall Street Has Questions
- Netflix Is Making Big Changes, But Can It Fix What’s Really Hurting Growth?
- Charging Ahead: Solid Power’s Pilot Line Leaves the Lab
Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.
